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Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative brain disease presenting with a variety of motor and non-motor 
symptoms, loss of midbrain dopaminergic neurons in the substantia nigra pars compacta and the occurrence of α-synuclein-
positive Lewy bodies in surviving neurons. Here, we performed whole exome sequencing in 52 early-onset PD patients 
and identified 3 carriers of compound heterozygous mutations in the ATP10B P4-type ATPase gene. Genetic screening of 
a Belgian PD and dementia with Lewy bodies (DLB) cohort identified 4 additional compound heterozygous mutation car-
riers (6/617 PD patients, 0.97%; 1/226 DLB patients, 0.44%). We established that ATP10B encodes a late endo-lysosomal 
lipid flippase that translocates the lipids glucosylceramide (GluCer) and phosphatidylcholine (PC) towards the cytosolic 
membrane leaflet. The PD associated ATP10B mutants are catalytically inactive and fail to provide cellular protection 
against the environmental PD risk factors rotenone and manganese. In isolated cortical neurons, loss of ATP10B leads to 
general lysosomal dysfunction and cell death. Impaired lysosomal functionality and integrity is well known to be implicated 
in PD pathology and linked to multiple causal PD genes and genetic risk factors. Our results indicate that recessive loss of 
function mutations in ATP10B increase risk for PD by disturbed lysosomal export of GluCer and PC. Both ATP10B and 
glucocerebrosidase 1, encoded by the PD risk gene GBA1, reduce lysosomal GluCer levels, emerging lysosomal GluCer 
accumulation as a potential PD driver.
Keywords Parkinson’s disease · Massive parallel sequencing · ATP10B P-type ATPase · Endo-lysosomal lipid flippase · 
Loss-of-function · Glucosylceramide
Introduction
Parkinson’s disease (PD) affects over 10 million people 
worldwide [13, 88, 89]. Clinically, patients display a vari-
ety of motor (e.g. resting tremor, bradykinesia, rigidity, and 
postural instability) and non-motor symptoms (e.g. demen-
tia, constipation, sleep disturbances), impeding their ability 
to perform basic everyday activities [22, 40]. Up to 30% of 
the patients with PD develop symptoms of dementia at a 
later stage of the disease [1]. To date, PD patients receive 
symptomatic treatment, though relief is temporary and not 
without adverse effects [32]. Neuropathological hallmarks 
of PD include the loss of midbrain dopaminergic neurons 
in the substantia nigra pars compacta and the presence of 
α-synuclein containing Lewy bodies in surviving neurons 
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[19, 29, 108]. Although inherited PD is rare with an esti-
mated frequency of 5–15%, the identification of high-pen-
etrant mutations in causal genes in monogenic PD families 
have been instrumental in dissecting PD disease etiologies 
[61, 85, 114]. To date, four genes are responsible for autoso-
mal recessive PD, associated with an early age at onset [58, 
61, 107, 110]. Bi-allelic mutations in PARK2 are the most 
common cause of autosomal recessive PD [86], explaining 
approximately 15% of early onset PD (EOPD) patients with 
an age at onset of 40–50 years [2], leaving a large fraction 
of EOPD patients genetically unexplained. In PD patient 
cohorts, genome-wide association studies (GWAS) identi-
fied over 70 loci with variable genetic contributions to PD 
risk [74]. Together these causal and risk genes represent only 
a small fraction of the genetic etiology of PD leaving both 
PD families and sporadic PD patients genetically unsolved. 
The knowledge acquired from the protein products of PD 
associated genes indicates that mitochondrial dysfunction, 
impaired intracellular trafficking, dysfunctional autophagy-
lysosomal protein degradation pathways and α-synuclein 
aggregation are associated with neuronal death in PD [3, 
17, 33, 44, 78, 117]. Several PD associated genes regulate 
membrane dynamics wherein mutations cause lipid homeo-
stasis alterations associated with lysosomal dysfunction 
[34, 35, 65]. In particular, mutations in GBA1 encoding the 
lysosomal enzyme glucocerebrosidase (GCase) increase the 
risk for PD with an estimated odds ratio of 5.4 [99]. GCase 
is involved in sphingolipid metabolism by catalyzing the 
breakdown of glucosylceramide (GluCer) and glucosyl-
sphingosine (GluSph) to ceramide and sphingosine respec-
tively in the lysosome [15, 30]. Up to 7–12% of PD patients 
carry mutations in GBA1, and hence GBA1 is the most com-
mon genetic risk factor [23, 30, 100].
PD shows clinical, pathological and etiological overlap 
with dementia with Lewy bodies (DLB) and both diseases 
can be viewed as a continuum rather than dichotomous 
entities [46]. In DLB, the sequence of onset of dementia 
and parkinsonism is contrariwise compared to PD, with 
the initial cognitive deterioration resembling that of other 
dementias. DLB represents 10–25% of all dementias, only 
second to Alzheimer’s disease (AD) [47], and Lewy bodies 
are diffusely distributed throughout the cortices of the brain 
of DLB patients [105]. Novel candidate genes for either PD 
or DLB should be investigated in patients with the other 
phenotype as well, as the same genes may contribute to the 
development of both diseases, like SNCA and GBA1 [45, 
75, 81].
Via whole exome sequencing (WES) in 52 unrelated 
early-onset PD (EOPD) patients, we identified compound 
heterozygous mutations in the P4 transport ATPase class 
V type 10B gene (ATP10B) in 3 EOPD patients. The unaf-
fected parents of these 3 EOPD patients each carried one 
variant in ATP10B, confirming trans configuration in the 
patients and as such recessive inheritance. Targeted rese-
quencing of ATP10B in a Belgian PD and DLB cohort iden-
tified four additional patients carrying compound heterozy-
gous mutations. We established that ATP10B encodes a late 
endo-lysosomal GluCer and phosphatidylcholine (PC) lipid 
flippase in which patient associated compound heterozygous 
mutations impair functional activities of ATP10B. Loss of 
ATP10B results in lysosomal dysfunction and sensitizes 
cortical neurons to cell death. Both ATP10B and GCase 
function in the same pathway regulating lysosomal GluCer 
content. Our genetics and functional data suggest that com-
pound heterozygous ATP10B mutations contribute to risk for 
PD and DLB by a loss-of-function mechanism resulting in 




The PD cohort consisted of 617 unrelated patients (mean age 
at onset (AAO) 60.0 ± 11.5 years, 31.8% women, 18.6% with 
a positive familial history) and the DLB cohort consisted of 
226 unrelated patients (mean AAO 70.8 ± 9.8 years; 32.7% 
female, 23.0% with a positive familial history) recruited in 
the framework of the Belgian Neurology (BELNEU) Con-
sortium, a multicenter collaboration of neurology expertise 
centers in Belgium [20, 41]. Index patients were evaluated 
with a detailed clinical history of patients and family, clini-
cal neurological examination, and neuroimaging. All PD 
patients fulfilled the National Institute of Neurological Dis-
orders and Stroke (NINDS) diagnostic criteria for PD [40], 
whereas DLB patients were diagnosed in accordance with 
the established criteria for possible, probable or pathological 
DLB [71]. In the DLB cohort, 70 patients received a neuro-
pathological diagnosis of DLB and 113 patients received a 
clinical diagnosis of probable DLB. Patients with a positive 
familial history have at least one first-degree relative pre-
senting with PD or dementia. EOPD, was defined as PD with 
age at onset ≤ 50 years, and was observed in 120 patients of 
the PD cohort (mean AAO 43.4 ± 5.9 years, 24.2% women, 
18.3% with a positive familial history). Of the EOPD 
patients, we collected detailed familial information and 
bio-sampled available family members. The complete PD 
cohort was genetically profiled for the 5 major PD genes 
(SNCA, LRRK2, PARK2, PINK1 and PARK7) by means 
of Sanger sequencing for simple mutations, and multiplex 
amplicon quantification (MAQ, Agilent, Multiplicom, Niel, 
Belgium), quantitative real-time PCR or multiplex ligation-
dependent probe amplification (MLPA) [50] for copy num-
ber variants [79]. Additionally, VPS13C was screened using 
a custom-designed gene panel (MASTR technology, Agilent, 
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Multiplicom, Niel, Belgium) [42] followed by massive paral-
lel sequencing on a MiSeq sequencing platform (Illumina, 
San Diego, CA, USA). We selected 52 unrelated EOPD 
patients (mean AAO 41.7 ± 6.7, 28.8% women, 23.1% with 
a positive familial history) with documented family history 
of disease and no disease-causing PD mutations for WES to 
search for novel PD genes.
A geographically-matched cohort, using self-reported 
ethnicity data, consisted of 598 unrelated control individu-
als with a mean age at inclusion (AAI) of 70.4 ± 7.9 years 
(67.7% female). Some control individuals were partners of 
the patients visiting a clinical neurology department, and 
who were screened for neurological or psychiatric anteced-
ents and neurological complaints. The majority of the con-
trol individuals were community-dwelling volunteers, who 
tested with a score > 25 on a Montreal Cognitive Assessment 
(MoCA) [76] and without personal or familial history of 
neurodegenerative or psychiatric diseases.
Whole exome sequencing
WES was performed on high molecular weight genomic 
DNAs of the selected 52 EOPD patients. The  SeqCap® EZ 
Human Exome Probes v3.0 (Roche) was used for exome 
enrichment for 23 patients followed by library sequencing 
on a NextSeq 500 platform (Illumina; ≥ 20 × coverage of 
RefSeq [80] coding region: 90.3 ± 1.88%). The SureSe-
lect All Human Exon V5 + UTR enrichment (Agilent) was 
applied for 10 patients (≥ 20 × coverage of RefSeq [80] 
coding region: 87.3 ± 0.80%), the Nextera Rapid Capture 
Exome (Illumina) for 1 patient (≥ 20 × coverage of RefSeq 
[80] coding region: 61.18%) and the Nextera Rapid Capture 
Expanded Exome (Illumina), for 2 patient (≥ 20 × coverage 
of RefSeq [80] coding region: 78.13 ± 0.78%) followed by 
sequencing on a HiSeq 2000 platform (Illumina). The Bur-
rows-Wheeler Aligner (BWA) [62] was used to perform the 
sequence alignment to the reference genome GRCh37 (hg19, 
UCSC Genome Browser). Variant calling was done with 
Genome Analysis Toolkit (GATK) Unified Genotyper [27, 
72]. For 16 patients, exome enrichment was performed using 
the TargetSeq Exome Enrichment kit (Thermo Fisher Scien-
tific, https ://www.therm ofish er.com) followed by sequencing 
on the SOLiD™ 5500xl Wildfire system (Thermo Fisher 
Scientific; ≥ 20 × coverage of RefSeq [80] coding region: 
64.1 ± 6.75%). Here, read alignment and variant calling ware 
performed using the LifeScope™ Genomic Analysis Soft-
ware (Thermo Fisher Scientific). GenomeComb, an in house 
developed package designed for analysis of massive parallel 
sequencing data, was used to annotate and select variants 
[91]. Because recessive PD genes are associated with an 
early onset age, we focused on homozygous and putative 
compound heterozygous variants (≥ two variants in one 
gene) with the following criteria: No occurrence or a minor 
allele frequency (MAF) ≤ 5% in Genome Aggregation Data-
base (gnomAD) and < 25% in an in-house next generation 
sequencing (NGS) database of probands with distinct neuro-
degenerative brain disorders; variants with impact on protein 
level (non-synonymous missense, nonsense, frameshift, and 
splice site variants); high quality variants (coverage ≥ 15, 
genomic location outside repeat regions marked as simple 
repeats or micro satellites by RepeatMasker v3.0 [103]. 
Genes with autosomal recessive variants in 3–4 EOPD 
patients received the highest priority as well as genes with 
functional annotations related to known PD pathways.
Whole genome sequencing
Whole genome sequencing (WGS) of EOPD patient DR621 
and unaffected parents, subsequent read alignment to the 
human reference genome (NCBI build 37) and base and 
variant calling were performed by Complete Genomics™ 
Inc [31]. A minimum coverage of 20 × was obtained for 
93.0 ± 2.2% of the bases. GenomeComb was used for variant 
annotation and selection [91]. Low coverage (< 20 ×) vari-
ants in addition to variants located in tandem repeats or high 
variability clusters were excluded from further analyses. We 
focused on exonic non-synonymous variants with a MAF 
less than 5% in the 1000 Genomes Project database or below 
25% in an in- NGS database of probands with distinct neuro-
degenerative brain disorders. Variants were selected in line 
with the following inheritance patterns: X-linked, de novo, 
autosomal compound heterozygous recessive (in trans) or 
autosomal homozygous recessive. Validation of the selected 
variants in DNA samples of DR621 as well as variant geno-
typing in unrelated control individuals was performed using 
iPLEX Gold chemistry on the Sequenom MassARRAY 
platform followed by MALDI-TOF mass spectrometry, or 
by direct Sanger sequencing on an automated ABI3730xl 
DNA analyzer (Applied Biosystems). Primers were designed 
with either MassARRAY Assay Design software v.3.0.2.0 
(Sequenom Inc) or Primer3. Genotypes were automatically 
called using MassARRAY Typer software v4.0 (Sequenom 
Inc) or the NovoSNP software package and visually checked 
according to GLP principles [116]. Variation combinations 
were assigned a lower priority for follow-up when present 
in aged control individuals. In case of X-linked variations, 
only genotypes of male individuals were accounted for. 
Homozygosity mapping of the WGS data using PLINK was 
performed as described elsewhere [55]. Homozygosity map-
ping did not reveal homozygous regions larger than 1 Mb in 
DR621, indicating that homozygous variants are unlikely to 
be pathogenic in the proband. Structural variants (SV) were 
called by Complete Genomics™ Inc [31] and a SV detec-
tion tool integrated in GenomeComb [91]. In silico disease-
network analyses were performed using four algorithms: 
SUSPECTS, ToppGene, Endeavour and Biograph [4, 5, 63, 
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99]. These prediction programs rely on distinct combinations 
of features and metrics to link a predefined disorder with 
a set of candidate genes. The known genes for recessively 
inherited early-onset PD (PARK2, PINK1, and PARK7) and 
recessively inherited juvenile- or early-onset atypical parkin-
sonian syndromes (FBXO7, ATP13A2 and PLA2G6) were 
used as training parameters. Candidate gene prioritization 
programs nominated ATP10B as the most likely disease gene 
in this family. Sanger sequencing was used to sequence the 
coding region and splice site junctions of all eight candidate 
genes in 120 EOPD patients.
Targeted resequencing of ATP10B
PCR amplification of all 26 exons and flanking splice sites 
of ATP10B (NM_025153) was performed by a custom-
designed amplicon-target PCR amplification assay (MASTR 
technology, Agilent, Multiplicom, Niel, Belgium) [42]. 
Amplicons were uniquely tagged; based on the Nextera XT 
shotgun library preparation protocol (Illumina, San Diego, 
CA, USA), containing sample-specific indices [59]. Librar-
ies (n = 975) were pooled and sequenced in one run on the 
MiSeq platform using the MiSeq V3 chemistry, generating 
paired-end sequence reads of 300 nucleotides (Illumina, 
San Diego, CA, USA). After sample de-multiplexing, 
adapter clipping was performed with fastq-mcf [10] and 
sequence reads were mapped using the Burrows–Wheeler 
Aligner (BWA) [62] to a mini-genome, combining the tar-
get sequences extracted from the human genome reference 
sequence hg19. Primer sequences were clipped out using the 
sam_clipamplicons tool in Genomecomb [91]. The mean 
percentage > 20 × coverage of all target amplicons in 1441 
samples (PD, DLB and control cohort) was 99.32 ± 1.92%. 
Sequence variants were called with GATKv2.4 UnifiedGen-
otyper and GATKv3.5 HaplotypeCaller [27, 72], and anno-
tated using GenomeComb [91]. The option -dcov 1000 in 
GATK was used to downsample reads as of > 1000 reads 
per sample. We focused on homozygotes and compound 
heterozygotes (e.g. ≥ 2 variants per individual) with a fre-
quency < 0.01%. Coding variants were numbered according 
to the GenBank Accession Number NM_025153 and amino 
acid changes according to the GenPept Accession Number 
NP_079429.
Variant genotyping
Candidate variants identified in the WES/WGS data were 
validated and genotyped in relatives whenever possible by 
PCR amplification of genomic DNA followed by Sanger 
sequencing using the  BigDye® Terminator Cycle Sequenc-
ing kit v3.1 (Applied Biosystems) on an ABI3730 automated 
sequencer (Applied Biosystems). Primers were designed 
using the online Primer3 software [95]. Sanger sequencing 
was also used for the validation of rare (MAF < 5%) non-
synonymous coding and splice site variants identified by 
targeted resequencing of ATP10B.
Haplotype sharing analysis
Haplotype sharing between the relatives was analyzed 
by genotyping 15 polymorphic short tandem repeat 
(STR) markers surrounding ATP10B at chromosome 
5q34: GATA139B09, D5S2090, D5S2013, D5S673, 
D5S2007, D5S1507, D5S2049, D5S412, D5S2038, 
chr5:159987161–159987527, chr5:160120387–160120617, 
D5S529, D5S422, D5S2066 and D5S2040. The STR mark-
ers were PCR amplified using fluorescently-labeled primers 
and size-separated using GeneScan 600 LIZ Dye Size Stand-
ard (Applied Biosystems) on an ABI3730xl DNA Analyzer 
(Applied Biosystems). Fragment lengths were scored using 
the in-house developed Local Genotype Viewer genotyping 
software (https ://www.neuro micss uppor tfaci lity.be/).
In silico splicing prediction
The splicing effect was evaluated in silico according to 4 
splicing prediction programs (SpliceSiteFinder-like, Max-
EntScan, NNSPLICE and GeneSplicer) integrated in Ala-
mut Visual version 2.11.0 (Interactive Biosoftware, Rouen, 
France).
Quantitative real time PCR
Total RNA of five substantia nigra and six medulla oblongata 
samples from six idiopathic PD patients without ATP10B 
mutations and four substantia nigra and medulla oblongata 
samples from four age- and gender-matched control indi-
viduals without neurologic pathology (provided by the Ant-
werp Biobank at the institute Born-Bunge) was extracted 
using the Ribopure kit (Ambion) and DNAse treated (Turbo 
DNAse kit, Ambion). Total RNA originating from a variety 
of human tissues (Life Technologies, AM6000) and brain 
regions, including substantia nigra (Clontech), cerebellum 
(Agilent Technologies), frontal cortex (Agilent Technologies 
& Stratagene), temporal cortex (Clontech & Biochain), pari-
etal cortex (Aligent Technologies & Ambion), occipital cor-
tex (Clontech), medulla oblongata (Biochain), striatum (Agi-
lent Technologies), hippocampus (Clontech & Biochain), 
and basal ganglia were purchased. RNA concentrations and 
integrity were evaluated on a 2100 Bioanalyzer (Agilent 
Technologies). cDNA synthesis (Superscript III First-Strand 
synthesis, Thermofisher) was performed with both random 
hexamer and oligo (dT) primers. ATP10B expression was 
examined by SYBR green-based quantitative real time PCR 
(qRT-PCR, ATP10B ex10 FW: TCA TCC TCA TGT GCC 
TTA TTGG & Rev: TGT TCT TCAAA GGT CCC ATTCC; 
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ATP10B ex17 FW: TCA TGG AAA CTG CAC AGC ATCT & 
Rev: CTG CAG CCG GTC TTC GAT ). At least two reference 
genes were included in the experimental setup, based on 
their stability as calculated by Qbase+ (Biogazelle, HPRT1 
FW: TGA CAC TGG CAA AAC AAT GCA & Rev: GGT CCT 
TTT CAC CAG CAA GCT; GAPDH FW: ACG GGA AGC 
TTG TCA TCA ATG & Rev: GCA TCG CCC CAC TTG ATT 
T; YWHAZ FW: CAC AAG CAGAG AGC AAA GTC TTC 
TAT & Rev: AGC TTC TTG GTA TGC TTG TTG TGA ). All 
samples were run in triplicates. Normalization of ATP10B 
values and calculation of the relative mRNA expression lev-
els was performed using Qbase+ software. Knockdown was 
verified with quantitative RT-PCR on RNA isolated from 
transduced and selected cells with the following primers: 
FW CTT CTA CAT GTT CCT CAC AAT GAT CA, Rev GCT 
CAA TGG AGA CAT ACA AAG AGA TG (human); FW CTT 
CTA TAT GTT CCT CAC AAT GATCA, Rev GCT CAA TGG 
ACA CAT ACA AGG AGA TC (mouse).
Tissue culture maintenance
HeLa, Hek293T (Dharmacon, HCL4517), Im95m (JCRB 
cell bank, JCRB1075.1) and WM115 cell lines (Sigma, 
91061232) were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) culture media containing 1% l-glu-
tamine and penicillin/streptomycin (Sigma-Aldrich; G7513 
and P0781, respectively) as well as 10% fetal bovine serum 
(FBS; Life Technologies, 10270106). Im95m cells were cul-
tured with 10 µg/ml insulin in the medium (Sigma-Aldrich; 
I9278). Cells were cultured for a maximum of 20 passages.
Viral transductions
For viral transductions, 100,000 of either ATP10B negative 
HeLa, or endogenously expressing WM-115 or Im95m cells 
or 200,000 isolated cortical neurons were plated per well in 
24-well plates. For overexpression, HeLa cells were trans-
duced with lentiviral vectors coding for Cell Cycle Control 
Protein 50A (CDC50A) and ATP10B (encoding for the wild 
type (WT), catalytic dead mutants p.E210A and p.D433N, 
disease mutants p.R153*, p.G671R/p.N865K, p.V748L, 
p.E993A, p.I1038T, p.T161N, p.G393W, p.G6487R, 
p.I1222T and the polymorphism p.C217R or an enhanced 
green fluorescent protein (eGFP)-tagged WT and p.D433N 
variant). After lentiviral transduction, cells were selected 
with hygromycin (CDC50A, 200 µg/ml; Invitrogen, Ant-
hg-1) or puromycin (ATP10B variants, 2 μg/mL; Invitrogen, 
Ant-pr-5) before confirmation by immunoblotting. For dou-
ble transduction cells were first transduced with CDC50A 
vector, selected with hygromycin, and then transduced with 
the different ATP10B viral vectors. For knockdown, micro-
RNA (mir) based short-hairpin lentiviral vectors were gen-
erated as described [82]. Viral vectors against 5 (human) 
to 7 (mouse) different target sequences were produced and 
validated for functionality. The most potent mir against each 
target were further used in this study (human mir2: ATG 
ATT CAA GCT GCT GAT ATTG, human mir3: ACT TTG CCA 
TCA CCC GCT TTAA, human mir5: ACC TTA AGC TAG 
TAC CTA TATA, mouse mir5: TCC TGG TGA TTC TGA ACT 
GGAT, mouse mir7: CCC TAA GAC AGT GCC TAT ACAT). 
A mir against firefly luciferase (mirFluc, ACG CTG AGT 
ACT TCG AAA TGTC) was used as control [82]. Transduced 
knockdown cell lines were selected with blasticidin (10 µg/
ml, Invivogen).
Transient transfection
For the subcellular localization of ATP10B, stable eGFP-
ATP10B WT or eGFP-ATP10B p.D433N cell lines were 
transiently transfected with either an endo-/lysosomal 
marker (Rab5-mCherry, Rab7-mCherry, LAMP1-mCherry) 
or an endoplasmic reticulum (ER) marker (Serca-mCherry) 
using Lipofectamine 2000 (Thermo Fischer Scientific, 
11668-027, at a ratio of 3:1) for 8 h in FBS free media prior 
to overnight incubation in full culture media. The cells were 
washed with PBS (Life Technologies, 14190169) and fixed 
(30 min, 37 °C) with 4% paraformaldehyde (PFA, Affym-
etrix, 199431LT).
Neuron Isolation and experimental culture
Primary cortical neurons were derived from E16 FVB/N 
mice embryos. Pregnant mice were sacrificed on gesta-
tion day 16 by cervical dislocation. E16 mice pup brains 
were collected and placed in a dish containing calcium- and 
magnesium-free Hanks’ Balanced Salt Solution (HBSS, 
Life Technologies, 14180-046) on ice. Both cerebral hemi-
spheres were separated from the cerebellum. Meninges 
were removed from the cerebral hemispheres and brain cor-
tices were dissected. Brain cortices were collected, washed 
twice and digested with 0.05% trypsin (Life Technologies, 
25300-054, 10 min at 37 °C). Trypsin reaction was stopped 
by adding 7 ml of HBSS and 1 ml of horse serum. Cells 
were separated by pipetting and filtration through a 40 μm 
cell strainer (Falcon, 352340). Cells were centrifuged for 
5 min at 1000 rpm (4 °C), the supernatant removed and 
the pellet suspended in 5 ml Dulbecco’s Modified Eagle 
Medium (DMEM; Sigma-Aldrich, D6546) + GlutaMAX 
(Life Technologies, 31966-021) containing 5% horse serum 
(Life Technologies, 26050-088) and 20 mM glucose (Sigma-
Aldrich, 8270). Primary cortical neurons were plated in 
the relevant well plates, coated with poly-d-lysine (Sigma-
Aldrich, P6407). After an overnight incubation, cell medium 
was exchanged for Neurobasal medium (Life Technologies, 
21103-049) supplemented with 2% B27 (Life Technolo-
gies, 17504-044) and 2 mM l-glutamine (Life Technologies, 
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25030-24). At 3 days in vitro (DIV) the neurons were trans-
duced with two independent ATP10B targeting mir’s, utiliz-
ing mirFluc as a control. For recovery of ATP10B expression 
within experimental knockdown conditions, lentiviral based 
overexpression of ATP10B or p.D433N was performed on 
DIV 4. Fluc was used as a control. At DIV 6, neurons were 
treated and experiments were terminated at DIV 7.
Treatments and reagents
Cell lines and isolated neurons were treated with indicated 
doses of rotenone (dimethyl sulfoxide (DMSO), 0–10 µM; 
Sigma-Aldrich, R8875), zinc  (ZnCl2, 0–10 µM, Sigma-
Aldrich, Z0152), the proteasome inhibitor bortezomib 
(phosphate buffered saline (PBS), Bort, 100 nM; Bio-Con-
nect BV, 354938) or manganese (PBS,  MnCl2 0–1 mM; 
CASP, 25,605) for 48 h. Apoptosis was blocked by a 1 h 
pre-incubation with the caspase inhibitor Zvad-fmk (DMSO, 
Zvad, 50 µM; Bachem, N1560-0005). Lysosomal function-
ality was blocked by a 1 h pre-treatment with bafilomycin 
(BAF A1, 50 nM or 1 µM; Sigma-Aldrich, B1793-10UG). 
In non-treated conditions, vehicle was used as a control. For 
the experimental use of lipids, lipid stocks were prepared 
in 100% chloroform and a lipid film was formed by evapo-
ration under nitrogen. Finally, lipids were re-suspended in 
either 95% ethanol (translocation assays) or reaction buffer 
supplemented with 10  mM of 3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfonate hydrate (CHAPS, 
ATPase assay).
Autophosphorylation assay
HeLa microsomes were prepared according to [49]. The 
assay was performed as previously described [48] with 
minor adaptations. Firstly, during microsomal preparation 
ATP10B was isolated in styrene maleic acid co-polymer 
(SMA) lipid particle-based microenvironment (SMALP), 
whereby the SMA co-polymer (PolySoMA, Uispac) was 
added to a final concentration of 2.5% (wt/vol) before the 
final ultracentrifugation step. Secondly, for the detection 
of ATP10B phospho-enzyme a reaction time of 5 min was 
used.
ATPase assay
HeLa microsomes were prepared [49]. ATPase activ-
ity was assessed using the commercially available ADP-
Glo MAX assay (Promega). Briefly, 5 µg of microsomes 
were plated per well in a white 96-well plate, in 50 mM 
3-(N-Morpholino)propanesulfonic acid (MOPS), 100 mM 
KCl, 11 mM  MgCl2, 1 mM Dithiothreitol (DTT), 195 µM 
n-dodecyl-d-maltoside (DDM, pH 7, KOH) and allowed to 
equilibrate on ice for 1 h, placed at 37 °C for 5 min prior to 
the stimulation of ATPase activity by the addition of 5 mM 
ATP for 30 min (37 °C). Reactions were terminated by Glo 
MAX assay reagent addition and luminescence was moni-
tored after 1 h using a Flexstation 3.0 microplate reader. To 
determine the effect of lipid substrate addition on ATP10B 
ATPase activity, 10 µg of microsomes were plated per well 
in a white 96-well plate, in 50 mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES), 150 mM KCl, 
12.5 mM  MgCl2, 1 mM DTT (pH 7, KOH) with 500 µM 
phosphatidylcholine, 500  µM glucosylceramide or the 
combination (250 µM of each lipid) and reactions were per-
formed as described above.
Lipid translocation assay
HeLa microsomes were prepared according to [49]. ATP-
dependent nitrobenzoxadiazole (NBD) phospholipid trans-
locase activity was measured as described by [77], with 
some minor adaptations. In brief, microsomal membranes, 
harvested from stable HeLa cells overexpressing ATP10B 
WT or p.D433N, were assayed for ATP10B-dependent flip-
pase activity using a back-extraction method. Equal volumes 
of microsomes, NBD-lipids (10 µM) and ATP regenerating 
system (without ATP) were mixed together and incubated 
for 1 h on ice to allow incorporation of the NBD-lipid into 
the cytosolic membrane leaflet. Subsequently, samples were 
incubated at 37 °C and after 2 h, ATP was added to stimulate 
ATP10B-dependent flippase activity. At hourly time points, 
3 aliquots of 15 μl each were removed and added to one 
tube (A) containing 7.5 μl of buffer H (10 mM HEPES, pH 
7.5, 150 mM NaCl) and two tubes (B, C) containing 7.5 μl 
of 3% fatty acid-free bovine serum albumin (BSA, Merck-
Millipore) in buffer H. After 5 min on ice, 177.5 μl of ice-
cold buffer H was added to each tube, and samples A and 
B were centrifuged at 150,000×g for 15 min (4 °C), while 
sample C was left on ice. The supernatants from samples A 
and B and the entire sample C were transferred to a 96-well 
plate and mixed with 200 μl 2% Triton X-100 in buffer H. 
The NBD fluorescence of each sample was measured using 
a fluorescence plate reader (FlexStation, Molecular Devices) 
with excitation at 467 nm and emission at 534 nm (cut-off 
530 nm). The percentage of NBD-phospholipid in the cyto-
solic membrane leaflet was calculated as described in [77]. 
To investigate the effect of disease mutations or substrate 
specificity experiments were performed as 4 h endpoint 
measurements. For substrate specificity, competition experi-
ments were performed with the aforementioned procedure; 
however the membrane fraction were incubated with NBD-
PC or NBD-GluCer alone or in combination with a spectrum 
on non-NBD labeled lipids (10 µM), equilibrated on ice for 
1 h followed by 37 °C for 2 h. Flippase activity was activated 
by the addition of ATP and terminated 2 h later. Samples 
were collected and assessed as described above.
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Co‑immunoprecipitation
HEK293T cells were lysed 48 h post-transfection in lysis 
buffer (25 mM Tris–HCl, pH 8.0, 150 mM NaCl, 2% Noni-
det P-40, supplemented with complete protease (Roche) and 
Phospho-STOP (Sigma) inhibitor mixtures) for 30 min on 
ice and cleared by centrifugation (10 min, 20,000×g). Pro-
tein concentration of the supernatant was determined using 
a bicinchoninic acid (BCA) protein assay (Pierce™). 1 mg/
ml of all cell lines was incubated overnight in the presence 
of protein G Dynabeads™ (Thermo Fisher Scientific) and 
HA antibody (Cell signaling, 3724) or normal rabbit IgG 
antibody (Santa Cruz, sc-2027) at 4 °C on a rotating device. 
Afterwards, the beads were collected and washed repeatedly 
with the lysis buffer. Finally, beads were re-suspended in 
lysis buffer supplemented with 4 × LDS sample buffer and 
100 mM DTT, boiled for 10 min at 95 °C, and loaded on 
4–12% Bis–Tris NuPAGE gels (Life Technologies).
Split luciferase assay
A protein complementation assay based on firefly lucif-
erase was used to show interaction between ATP10B and 
CDC50A, with eGFP as a control. Plasmids for the N- and 
C-terminal parts of luciferase were generated that fused to 
ATP10B WT, CDC50A and eGFP was used as a control. 
20,000 HEK293T cells were plated 20,000 cells/well in a 
96-well plate and transfected with different combinations 
of the aforementioned plasmids. Luciferase activity was 
measured 48 h after transfection using the ONE-Glo Lucif-
erase Assay System (Promega) and is used as a measure for 
protein interaction between the N- and C-terminal parts of 
luciferase.
Immunoblotting
HeLa microsomes were prepared according to [49] and 
immunoblotting was performed as previously described 
[113]. For total cell lysate investigation, cells were lysed 
using RIPA buffer (ThermoFisher Scientific, 89900) and 
DNA excluded by centrifugation (15,000×g for 15 min). 
Briefly, western blots of typically 20–40 µg of protein were 
ran on 4–12% Bis/Tris gel (NuPage, Thermo Scientific, 
NP0323BOX) and transferred to a 0.45 µm PVDF mem-
brane (Immobilon-P, Thermo Scientific, 88518) and probed 
for ATP10B (Sigma-Aldrich, HPA034574), CDC50A (anti-
FLAG antibody; Sigma-Aldrich, F3165). Cell death was 
assessed using a cleaved caspase 3 antibody (Cell signaling, 
9661). All blots were probed for either GAPDH (Sigma-
Aldrich, G8795) or β-actin (Sigma-Aldrich, C6198) as a 
loading control. Detection was performed using HRP-con-
jugated secondary antibodies (BIOKE, 7074S and 7076S). 
Detections were performed on a Bio-Rad Chemidoc Imager 
with Pierce ECL Western Blotting Substrate (Thermo Fisher 
Scientific, 32106). For co-immunoprecipitation experiments, 
PVDF membranes (Hybond P; Amersham Biosciences) 
were blocked in 5% skimmed milk in PBS and probed with 
primary antibodies against HA-tag (Covance, MMS-101P) 
and FLAG-tag (Novus Biologicals, NBP1-06712).
Immunofluorescence
After fixation with 4% PFA, cells were washed twice with 
PBS containing 0.5% tween 20 (PBS/T; Sigma-Aldrich, 
P1379) and permeabilized with 0.1% Triton X-100 
(Sigma-Aldrich, T9284) and 0.02% SDS (Acros Organics, 
230425000) containing PBS/T for 20 min. To minimize 
non-specific binding, 0.1 M Glycine in PBS/T was added 
to the cells after washing followed by blocking in PBS/T 
containing 1% BSA and 2% FBS. After washing, cells were 
incubated overnight at 4  °C with various primary anti-
bodies: Rab11 (Thermo Fisher Scientific, 71-5300), Rab5 
(Santa Cruz Biotechnology, Sc-46692), EEA-1 (Becton 
Dickinson, 610457), CD63 (BIO-CONNECT Diagnostics, 
11-343-C100), LAMP-1 (Abcam, ab24170), Rab7 (Abcam, 
ab137029 and ab25245), LAMP2 (Abcam, ab25339 and 
ab25631), ATP10B (Sigma-Aldrich, HPA034574) or cleaved 
caspase 3 (Cell Signaling, 9661) diluted according to manu-
facturer’s recommendations in PBS/T containing 0.1% BSA 
and 0.2% FBS. Finally, after the samples were washed with 
PBS-T, cells were incubated with Alexa Fluor dyes (Thermo 
Fisher Scientific, 1/2000) for 30 min. Nuclei were stained 
with DAPI (Sigma-Aldrich, D9542-10 mg). Cells were visu-
alized using an LSM780 confocal microscope.
Cell viability
Cells were seeded at 5000 cells per well in a 96-well plate. 
After treatment, cells were washed with PBS and incubated 
with 0.01 mg/ml MUH (4-methylumbelliferyl heptanoate; 
Sigma-Aldrich, M2514; dissolved in PBS) for 30 min at 
37 °C. Fluorescence was measured with a Flexstation 3.0 
plate reader (Molecular Devices, Wokingham, UK) at an 
excitation of 355 nm, emission of 460 nm, and cut off value 
of 455 nm.
Cell death
HeLa cells treated with rotenone or  MnCl2 were assessed 
for cell death induction as previously described [48]. 
Briefly, treated cells were collected at 48 h by trypsiniza-
tion, PBS-washed and exposed to 1 µg/ml propidium iodide 
(PI; Sigma-Aldrich, P4170-25MG) for 5 min. PI positivity 
was captured using an Attune flow cytometer (Life Tech-
nologies). Neuronal cell apoptosis was assessed by cleaved 
caspase 3 staining in accordance with the manufacturer’s 
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guidelines (Cell Signaling, 9661). Cortical neurons were 
plated with or without cover slips. Cells plated without cov-
erslips were ultimately assessed by flow cytometry using an 
Attune Flow Cytometer. Samples seeded on coverslips were 
imaged using a LSM780 confocal microscope (Leica). DAPI 
staining was used to visualize the nucleus.
TUNEL staining
Terminal deoxynucleotidyl transferase dUTP Nick-End 
Labeling (TUNEL) was assessed according to the manufac-
turer’s protocol for the Click-iT Plus TUNEL assay (Ther-
moFisher, C10617). Images were captured using a Leica 
LSM780 confocal microscope.
Fluorescein isothiocyanate‑dextran based 
lysosomal pH
WM115 cell lines were plated in 12 well plates (100,000 
cells per well) and allowed to attach overnight 37 °C. Cells 
were then exposed to 50 µg/ml fluorescein isothiocyanate 
(FITC)-dextran for 72 h. Samples were then washed, placed 
in fresh media, and treated with the appropriate stressors 
(1 µM Rotenone and 1 µM BAF A1) for 4 h. Samples were 
then collected by centrifugation (450×g, 5 min) and washed 
in PBS containing 1% BSA. Cells were finally re-suspended 
in 50 µl of PBS/BSA and FITC dual emission assessed by 
flow cytometry (excitation 488 nm, emission 530 (BL1) and 
600 (BL2) using an Attune NXT flow cytometer (invitro-
gen). The emission (BL1/BL2) of all samples were com-
pared to the signals obtained for control cells re-suspended 
in monensin (100 µM) containing Britton Robinson buffer 
with increasing pHs (3.0–8.0).
Lysosomal degradative capacity (DQ‑BSA)
Cells were seeded in 12-well plates (1.0 × 105 cells per well) 
and the next day, cells were pre-treated with rotenone for 1 h 
at 37 °C. 50 nM BAF A1 was used as an internal control. 
Subsequently, 5 µg/ml DQ Green BSA was added to the cells 
for a further 3 h (37 °C). Finally, cells were collected and the 
mean fluorescent intensities of 10,000 events were assessed 
using an Attune Nxt (Thermo Scientific) flow cytometer. For 
the assessment of lysosomal degradation capacity in isolated 
cortical neurons, cells were seeded in 12-well plates containing 
cover slips (3.0 × 105 cells per well) and the next day ATP10B 
was knocked down via lentiviral transduction. mirFluc was 
used as an internal transduction control. 48 h post lenti-viral 
exposure. ATP10B WT, p.D433N or Fluc were over-expressed 
via lentiviral transduction and allowed to incubate for a fur-
ther 24 h at 37 °C. Following rescue, cells were treated with 
10 µg/ml DQ-BSA for 1 h prior to treatment with rotenone 
(50 nM), and incubated further for 23 h at 37 °C. Cells were 
subsequently fixed, DAPI stained and images captured via con-
focal microscopy (Zeiss LSM780).
Lysosomal membrane integrity
To assess lysosomal membrane integrity, WM-115 cells were 
seeded in 12-well plates (1.0 × 105 cells per well) and the next 
day, cells were incubated with 5 µg/ml acridine orange (dis-
solved in media) for 15 min at 37 °C. Thereafter, medium was 
discarded, cells were washed and fresh medium was added. 
Cells were then treated with rotenone or the positive control 
BAF A1 (1 µM) for 4 h at 37 °C. Finally, cells were collected 
and resuspended in PBS containing 1% BSA. The mean fluo-
rescence of 10,000 events was captured using an Attune Nxt 
(Thermo Scientific) flow cytometer.
Statistics
To investigate association between recessive ATP10B muta-
tions and PD, mutation frequencies were statistically compared 
between the early-onset patient group and control individuals 
using Fisher’s exact statistics. ATP10B gene expression levels 
in PD patient brains versus brains of neurologically healthy 
individuals were statistically compared using a Mann–Whitney 
U test. Statistical significance of lipid translocation, cell death, 
and viability were performed by t test and one/two way analy-
sis of variance within GraphPad Prism 6.01. Pearson’s coef-
ficients were generated using Image J. Unless otherwise speci-
fied, data are represented as the average ± standard error of the 
mean (SEM) of a minimum of three independent experiments.
Ethical assurances
The genetic studies were approved by the ethic committee of 
the Antwerp University Hospital and the University of Ant-
werp. Clinical protocols were approved by the ethics com-
mittees of the main participating hospitals i.e. the Hospital 
Network Antwerp and the University Hospital Antwerp, as 
well as by the ethical review boards of the participating general 
hospitals which are participating via the BELNEU consortium. 
All human biological samples were collected in accordance 
with the written informed consents signed by the participants. 
All mouse primary neuron experiments were carried out in 
accordance with the European Communities Council Direc-
tive of November 24, 1986 (86/609/EEC) and approved by 
the Bioethical Committee of the KU Leuven (Belgium) (ECD 
project P185-2014).
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Results
Identification of compound heterozygous ATP10B 
mutations in patients
WES data was generated for 52 unrelated EOPD patients 
with an AAO below 50 years and negative for mutations 
in the major PD genes. We identified compound heterozy-
gous mutations in ATP10B in three EOPD patients DR621, 
DR741 and DR754 (Table 1; Table S1). Segregation analy-
sis of family members of these patients provided evidence 
for a trans location of the mutant ATP10B alleles (Fig. 1a). 
Additionally, WGS data were obtained for patient DR621 
and his parents, whom were neurologically healthy at ages 
of 75 and 72. Structural variants, including copy number 
variations, were excluded as a possible disease cause in the 
family. Candidate variant analysis of the WGS data identi-
fied eight candidate genes for PD, including ATP10B, but 
none with a de novo variant (Table S2). No rare or low-
frequency variants (MAF < 5%) in line with the proposed 
inheritance models were identified in the seven other 
candidate genes after screening 120 EOPD patients. This 
case-unaffected-parents trio approach to search for novel 
candidate genes independently nominated ATP10B as a 
candidate gene for PD in DR621.
Targeted resequencing of all exons and splice site junc-
tions of ATP10B in the Belgian cohorts of 617 PD and of 
226 DLB patients, identified three PD carriers and one 
DLB carrier of compound heterozygous ATP10B muta-
tions (Table 1). No prominent effect on splicing was pre-
dicted of the ATP10B c.3646-5T>C mutation in the DLB 
patient DR1504 (Table S3), though we were not able to 
assess the effect on mRNA splicing in the patient’s bioma-
terials because ATP10B mRNA expression is not detect-
able in blood (Fig. S2).
In total we observed in patients, 26 non-synony-
mous coding and splice site variants with a MAF < 5% 
in ATP10B (Fig. 1b) of which 14 variants were solely 
observed in patients (Fig. 1b, Table S4). The other 12 
variants were present at low frequency (MAF < 5%) in 
a matched Belgian control cohort (Fig. S1). More com-
mon, but probably benign compound heterozygous com-
binations (frequency > 0.01%) were observed in both the 
patient and control cohorts (Table S7).
Before, ATP10B was identified as a P4-type transport 
ATPase of unknown function present in the late endo-/
lysosomal compartment [73]. P4 ATPases are lipid flip-
pases that use ATP to drive the transport of lipids from 
the lumen to the cytosolic membrane leaflet, establish-
ing the vitally important lipid asymmetry between two 
membrane leaflets [8, 84]. We established that the mutant 
compound alleles in patients are mostly clustering around 
the catalytically nucleotide binding, phosphorylation, and 
actuator domains of ATP10B (Fig. 1c).
ATP10B mRNA expression is reduced in idiopathic 
patients
We analyzed ATP10B mRNA levels in different tissue sam-
ples and observed expression in the gastrointestinal system 
and the brain (Fig. S2a). In the brain, ATP10B expression 
was enriched in regions of PD pathology [16], predomi-
nantly in the medulla oblongata, substantia nigra, as well 
as the basal ganglia (Fig. S2b). ATP10B mRNA expression 
was further assessed in brain material of autopsy confirmed 
PD or DLB patients and control individuals and showed in 
patients a significant reduction in both the medulla oblon-
gata and the substantia nigra. (Fig. S2c, d).
ATP10B is a late endo‑/lysosomal GluCer/PC flippase
The yeast orthologs of ATP10B, Dnf1p and Dnf2p, trans-
port two classes of lipids, the phospholipid PC and the 
sphingolipid GluCer, whereas two close human isoforms, 
ATP10A and ATP10D, transport PC and GluCer respec-
tively in the plasma membrane [73, 94]. Moreover, most 
mammalian P4-type ATPases, including ATP10A-D, depend 
on CDC50A forming a heteromeric complex that facilitates 
exit from the endoplasmic reticulum [8]. In HeLa cells the 
CDC50A isoform 1 (Accession NP_060717.1) was shown 
to guide human ATP10B to the late endo-/lysosomes [73]. 
Here, we confirmed the interaction between CDC50A iso-
form 1 and ATP10B in HEK293T cells by co-immuno-
precipitation and split-luciferase protein complementation 
assays (Fig. S3a, b), and also observed a predominant late 
endo-/lysosomal localization of eGFP-labeled ATP10B 
(Accession O94823.2, longest isoform of 1461 amino 
acids) in HeLa cells co-expressing CDC50A (Fig. S4a, b). 
ATP10B contains typical hallmark motifs of other P4-type 
ATPases [12] (Figs. 1b, c, S1), and similar to other P4-type 
lipid flippases, ATP10B spontaneously forms a phospho-
intermediate (Fig. 2a, b). The autophosphorylation and sub-
sequent ATPase activities are fully abolished by mutating 
the phosphorylation acceptor residue p.D433 that is part of 
the catalytically important P-type ATPase signature motif 
433DKTGTLT (Fig.  2a, c). The eGFP-labeled p.D433N 
mutant is also well-expressed in the endo-lysosomal com-
partments of HeLa cells (Fig. S4c, d), and due to its lack of 
enzymatic activity the p.D433N mutant serves as an impor-
tant catalytic control for the functional assays to determine 
the biological transport activity of ATP10B, similar as in 
[111]. The p.D433N mutant is further used throughout this 
study as a loss-of-function control for the evaluation of the 
disease associated mutations.
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Based on sequence comparison and phylogenetic relation-
ship, we hypothesized that ATP10B may operate as a lipid 
flippase that exports GluCer and/or PC towards the outer 
membrane leaflet of the lysosome. Therefore, we performed 
a lipid translocation assay on isolated membrane fractions 
derived from HeLa cells stably overexpressing CDC50A 
with either ATP10B WT or p.D433N (Figs. 2d–f, S5) [73]. 
We followed the lipid translocation by determining the frac-
tion of fluorescent NBD-labeled lipids that are extractable 
from the accessible cytosolic membrane leaflet by fatty acid 
free bovine serum albumin. We observed spontaneous trans-
location of fluorescently labeled lipids from the cytosolic 
to exoplasmic membrane leaflet. Following ATP addition, 
ATP10B WT, but not the catalytic dead mutant p.D433N, 
promoted NBD-GluCer and NBD-PC translocation from 
the exoplasmic to cytosolic membrane leaflet (Fig. 2d, e). 
ATP10B did not translocate NBD-phosphatidylethanola-
mine, NBD-phosphatidylserine, NBD-phosphatidylglyc-
erol, NBD-galactosylceramide, NBD-ceramide, and NBD-
sphingomyelin (Figs. 2f, S5). Unlabeled PC and GluCer 
also stimulated the ATPase activity of ATP10B WT, but not 
p.D433N (Fig. 2g, h), further confirming the lipid specific-
ity, and indicating that the lipid dependent ATPase and trans-
location activities are coupled. Moreover, the co-incubation 
with PC and GluCer synergistically stimulated the ATPase 
activity of ATP10B more than PC or GluCer separately (at 
the same final lipid concentration), suggesting that the two 
lipids do not compete for the same substrate binding site. 
This was further verified by competition translocation assays 
demonstrating that equimolar concentrations of non-fluo-
rescent GluCer and PC compete only with the translocation 
of the corresponding NBD-labeled analogs (Fig. 2i). Also, 
a modest inhibitory effect of GluSph on NBD-GluCer, and 
sphingomyelin on NBD-PC translocation was observed. 
Together, we demonstrated that ATP10B is a late endo-/
lysosomal lipid flippase that translocates the lipids GluCer 
and PC towards the cytosolic membrane leaflet.
Disease associated mutants impair functional 
activities of ATP10B
We anticipated a loss of function mechanism similar to other 
autosomal recessive PD genes based on the identification 
of the premature stop codon mutation p.R153* in patient 
DR754. Moreover, all compound heterozygous missense 
mutations affect residues that are highly conserved across a 
diverse array of species (Fig. S6a), and are frequently posi-
tioned within conserved and functionally important domains 
of P-type ATPases (Fig. 1c). To investigate the effect of the 
compound heterozygous mutations in ATP10B identified in 
patients on the GluCer/PC translocation or ATPase activity, 
we transduced HeLa cells stably overexpressing CDC50A 
combined with ATP10B WT, two catalytic dead mutants 
p.D433N and p.E210A (mutation in dephosphorylation 
motif), mutants found compound heterozygous in patients 
(p.R153*, p.T161N, p.G393W, p.G648R, p.G671Rp.N865K, 
p.V748L, p.E993A, p.I1038T, p.I1222T) or a benign poly-
morphism (p.C217R, MAF 0.81). The resulting stable cell 
lines exhibited comparable ATP10B expression, except 
for the p.R153* truncation, which demonstrated a loss of 
protein expression when transfected into both HeLa and 
HEK293T cells (Figs. 3a, b, 6b). Moreover, full-length 
mutants retained their capacity to interact with CDC50A 
(Fig. S3c) highlighting similar interaction and trafficking 
as for wildtype ATP10B, allowing for an unbiased assess-
ment of their functionality. Functional assessment demon-
strated that all patient-associated mutants displayed impaired 
ATPase activity comparable to the catalytic dead mutants 
p.D433N and p.E210A (Fig. 3c). The reduced ATPase activ-
ity of the mutants correlated with an impaired NBD-GluCer 
and NBD-PC translocation activity (Fig. 3d, e), establishing 
a loss-of-function mechanism of the mutations compound 
heterozygous in patients. The loss of ATP10B function 
observed for the p.R153* mutant may be a consequence of 
the reduced expression levels in combination with the lack 
of catalytic domains. The p.I1222T mutant and the polymor-
phism p.C217R presented functional activities similar to WT 
ATP10B (Fig. 3c–e), indicating that p.I1222T is a benign 
variant. However, in patient DR754, this variant occurs in cis 
configuration with the damaging p.R153* mutation, while 
p.E993A, also presenting impaired functionality (Fig. 3c–e), 
is located in trans (Fig. 1a).
To investigate whether ATP10B exerts a cell protective 
effect, stable cell lines were exposed to the heavy metals 
 MnCl2 and  ZnCl2, the 26S proteasome inhibitor bortezomib 
and the mitochondrial complex I inhibitor rotenone, stress-
ors that evoked a phenotype in cell models of ATP13A2 
loss of function, another late endo-lysosomal P-type ATPase 
implicated in PD [26, 48, 68]. ATP10B WT significantly 
protected HeLa cells against rotenone and  MnCl2, but not 
against  ZnCl2 or Bortezomib (Fig. S7). Importantly, the dis-
ease-associated ATP10B mutants fail to provide cellular pro-
tection against rotenone and  MnCl2 exposure, analogous to 
the catalytic dead mutants and overexpression of CDC50A 
without ATP10B, whereas the benign variants p.I1222T and 
p.C217R were able to provide cellular protection against 
both stress conditions to the same extent as WT ATP10B 
(Fig. 3f, g). Addition of the caspase inhibitor Zvad-fmk sig-
nificantly blocked cell death, indicating that the observed 
cell death depends on apoptosis (Fig. S8).
ATP10B knockdown results in lysosomal dysfunction
To examine the consequences of ATP10B loss-of-function, 
we performed lentiviral based knockdown of ATP10B in 
two cell models presenting endogenous ATP10B expression. 
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Extensive screening of cell lines, including neuroblastoma 
cell lines, indicated sufficient endogenous ATP10B expres-
sion in the human adenocarcinoma Im95m and melanoma 
WM-115 cells (Figs. 4, S9). To induce a loss-of-function 
phenotype, we generated for each cell line two independ-
ent knockdown models using mir-based short-hairpins that 
demonstrated a reduction of > 60% of ATP10B mRNA (Fig. 
S9a, b) and undetectable protein expression (Figs. 4a, b, 
S9d). Control cell models were generated with mirFluc, a 
mir against the firefly luciferase gene (Fluc). Knockdown of 
ATP10B significantly increased the sensitivity of the cells 
to rotenone and  MnCl2 (Figs. 4c, S9c, g, h), but not to bort-
ezomib or  ZnCl2 (Fig. S9e, f, I, j), which was also observed 
in our mutant ATP10B overexpressing models (Fig. 3f, g), 
strengthening our conclusion that loss of ATP10B function-
ality increases cell toxicity towards PD-related insults.
To determine the underlying cause of cell death follow-
ing loss of ATP10B we assessed lysosomal functionality in 
WM-115 cells (Fig. 4d–h). ATP10B knockdown cells pre-
sented a significant loss of lysosomal mass (Fig. 4d, e) and 
a higher lysosomal pH (Fig. 4f) resulting in a global reduc-
tion of lysosomal degradative capacity (Fig. 4g). A further 
increase in lysosomal pH was observed following rotenone 
exposure in the ATP10B knockdown cell models, but not 
in control cells (Fig. 4f). Moreover, rotenone exposure in 
ATP10B knockdown cells impaired lysosomal membrane 
integrity (Fig. 4h), which is a major driver of lysosome-
dependent cell death [6].
ATP10B knockdown sensitizes mouse cortical 
neurons to cell death
We knocked down ATP10B in isolated mouse cortical neu-
rons to establish the link between loss of ATP10B and neu-
rodegeneration. Before knockdown, endogenous ATP10B 
expression in isolated mouse cortical neurons was verified 
by qRT-PCR and immunoblotting (Fig.  5a–c). Moreo-
ver, we confirmed the localization of ATP10B in CD63/
LAMP1-positive compartments via immunocytochemistry, 
demonstrating that also in neurons endogenous ATP10B is 
confined to the late endo-lysosomes (Fig. 5d, e). Post isola-
tion, ATP10B was knocked down in primary neurons via 
lentiviral shRNA transduction, which significantly reduced 
ATP10B expression (Fig. 5a–c) and correlated with a sig-
nificant increase in cleaved caspase 3 expression. Control 
mirFluc primary neurons were generated for comparison. 
To evaluate the protective effect of ATP10B in neurons, 
we first determined a dose response curve for rotenone and 
 MnCl2 toxicity and identified 50 nM rotenone and 0.5 mM 
 MnCl2 as potent inducers of caspase 3 induced cell death in 
the isolated neurons (24 h, Fig. S10). Importantly, ATP10B 
knockdown already sensitized neurons to cell death in basal 
conditions, as demonstrated by the cleaved caspase 3 and 
the TUNEL assay (Fig. 5b, c). Following exposure to either 
rotenone or  MnCl2, ATP10B knockdown neurons were 
even more susceptible to cell death (Fig. 5f–i). This phe-
notype could be rescued by ectopic expression of human 
WT ATP10B, but not by ectopic expression of the ATP10B 
p.D433N mutant (Figs. 6a, b, S10c, d), providing evidence 
that ATP10B activity is coupled to neuronal survival. 
Finally, ATP10B knockdown significantly reduced the deg-
radative capacity of the lysosomes in the neurons (Fig. 6c, 
d), which could also be rescued by the ectopic expression of 
human WT ATP10B, but not by expression of the p.D433N 
mutant of ATP10B.
Discussion
In our Belgian cohorts, we identified six PD patients (6/617; 
0.97%) and one patient clinically diagnosed with probable 
DLB (1/226; 0.44%), carrying compound heterozygous 
mutant alleles in ATP10B (Table 1). All 6 PD patients pre-
sented with a typical clinical PD phenotype, and two PD 
patients, DR741 and DR1140, developed cognitive dysfunc-
tion later in their disease course (Table S1). In the DLB 
cohort the frequency of ATP10B mutation carriers might be 
underestimated since obtaining an accurate clinical diagno-
sis of DLB is not obvious. A systematic review and meta-
analysis of the accuracy of the clinical diagnosis revealed 
that about 20% of DLB patients have an incorrect diagnosis, 
in most cases AD [93]. If we maintained in our DLB cohort 
only the patients with a clinical diagnosis of probable DLB 
(n = 113) or a neuropathological diagnosis of DLB (n = 70), 
the frequency of the compound heterozygous mutation car-
riers increased to 0.55%. All patient carriers of compound 
heterozygous ATP10B mutations tested negative for muta-
tions in major genes linked to different neurodegenerative 
brain diseases (Table S5). In the control cohort, we found 
Fig. 1  Genetic data of ATP10B in EOPD patients and the Belgian PD 
and DLB cohort. a Segregation data of ATP10B compound alleles in 
families of EOPD patients. DNA availability of relatives is indicated 
with an asterisk (*) and onset age of disease of patients and age at 
examination of unaffected relatives is indicated below the symbol. 
Numbers within each diamond represent unaffected at risk individu-
als included in the segregation analysis. Circles represent females; 
squares, males; filled symbols, patients; slash, deceased; arrowhead, 
index patient. b Linear representation of ATP10B with indication 
of all variants identified in PD and DLB patients. Domains based 
on the InterPro database [51], protein nomenclature according to 
NP_079429. Variants indicated in red are patient specific, variants 
indicated in blue were also found in control individuals, variants 
indicated in bold were found compound heterozygous in PD patients. 
c Schematic representation of ATP10B topology with indication 
of compound heterozygous variants in PD and DLB patients, and 
its interaction partner CDC50A, based on [8]. ATP10B motifs: 1, 
dephosphorylation site (208DGE); 2, substrate binding site (380PILS); 
3, phosphorylation site (433DKT); 4 and 5,  Mg2+ binding sites
◂
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two carriers of compound heterozygous ATP10B mutant 
alleles (2/597; 0.33%) (Table S6).
The compound mutant allele combinations in patients 
were rare (frequency < 0.01%) and specific for the patient 
cohort. Among the patient carriers the AAO varied from 
24 to 68 years, and in the two control carriers the AAI was 
69 and 75. The high variability in AAO and the presence 
of compound heterozygous mutant carriers in the control 
group is probable due to variable effects of single mutant 
alleles on ATP10B expression and their different combi-
nations in compound carriers. Variable penetrance likely 
leads to variable expression and functioning of ATP10B as 
shown in the functional in vitro studies (Fig. 3c–e). Incom-
plete penetrance of genetic alleles was also observed in 
LRRK2 and GBA1 mutation carriers [9, 67, 101].
The observation of six compound PD carriers versus 
two compound control carriers is suggestive of an enrich-
ment of compound heterozygous mutations in patients. 
However, the statistical analysis was not significant 
(p = 0.2879), most likely because of the small numbers 
in the Belgian cohorts. An estimation of the number of 
subjects needed for an adequate study power, taking into 
account the low frequency of compound heterozygous car-
riers, showed that a minimum of 5000 subjects (~ 2500 PD 
Fig. 2  ATP10B mediates the translocation of phosphatidylcholine 
and glucosylceramide. Microsomes of HeLa cells with stable over-
expression of CDC50A alone or in combination with either ATP10B 
WT or the catalytic p.D433N mutant were assessed for ATP10B 
expression and activity. Cells overexpressing CDC50A alone or co-
expressing the catalytic mutant p.D433N were used as negative con-
trols. a Upper part depicts a Western blot (WB) showing the compa-
rable expression levels of ATP10B WT and p.D433N versus GAPDH 
as loading control. Lower part depicts a representative radiogram of 
the 32P-ATP based autophosphorylation experiment (EP, phospho-
enzyme intermediate). The Coomassie gel staining was used as a 
loading control for the radiogram. b Bar graph summarizes the data 
of (a). c Differences in ATPase activity (ADP Glo assay) were inves-
tigated in ATP10B WT versus p.D433N or CDC50A-only membrane 
fractions. Reactions were initiated by the addition of 5 mM ATP and 
sustained for 30  min at 37  °C. Microsomes were assessed for their 
potential to translocate nitrobenzoxadiazole (NBD)-labeled phos-
phatidylcholine (NBD-PC, d) or NBD-glucosylceramide (NBD-Glu-
Cer, e) over time (0–4 h, 37 °C). We followed the lipid translocation 
by determining the fraction of fluorescent NBD-labeled lipids that is 
extractable from the accessible cytosolic membrane leaflet by fatty 
acid free bovine serum albumin (BSA). Following spontaneous trans-
location of fluorescently labeled lipids from the cytosolic to exoplas-
mic membrane leaflet (1–2 h), reactions were initiated by the addition 
of 1  mM ATP addition (at the 2  h time point). f Bar graph depicts 
the lipid specificity of ATP10B, showing that ATP10B preferentially 
translocates NBD-PC and NBD-GluCer (the bar graph summarizes 
the results of the translocation assay depicted in d, e and Fig. S3a–
f). g Dose response curve for the stimulatory effects on the ATPase 
activity of ATP10B WT of the non-labeled lipids PC and GluCer, 
alone or in combination. h ATPase activity of microsomes was meas-
ured under the presence of a final concentration of 500  µM PC or 
GluCer, alone or in combination. i The NBD-PC/NBD-GluCer trans-
location potential of ATP10B was assessed alone or in combination 
with equimolar addition of non-fluorescent PC, GluCer, phosphati-
dylserine (PS), ceramide (Cer), sphingomyelin (SM) or glucosyl-
sphingosine (GluSph) for 4 h at 37 °C. All data are the mean of three 
independent experiments. The immunoblots and autoradiograms are 
a representation of three independent experiments. Significance was 
determined by One Way ANOVA with either Dunnett’s (b, c, f, i) or 
Tukey’s (h) post hoc corrections. For time dependent lipid transloca-
tion assays (d, e), significance was assessed by Two Way ANOVA. 
In all cases *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001
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patients and ~ 2500 control individuals) would be required 
to reach 80% power.
Overall our results indicate that recessive mutations in 
ATP10B are associated with increased risk for PD, which is 
different from heterozygous dominant mutations in other PD 
risk genes. This might explain why ATP10B was not identi-
fied in large-scale PD GWAS studies using an allelic model 
[74]. Notably, homozygosity mapping and exome sequenc-
ing in 62 isolated individuals with early-onset parkinsonism 
and confirmed consanguinity, identified VPS13C as a can-
didate gene for autosomal recessive PD [61]. The use of a 
validation cohort [61], and an independent replication cohort 
confirmed a role for VPS13C in autosomal recessive PD [24, 
97]. Another whole exome sequencing study in 50 early-
onset patients with PD has nominated interesting variants in 
SPG7 [106]. Replication in exome data from 1148 European 
PD patients revealed significant association of heterozygous 
of p.A510V in SPG7 with PD risk [106]. Another independ-
ent study reported that parkinsonism is frequently observed 
in spastic paraplegia patients with pathogenic variants in 
SPG7 [25]. These examples demonstrated that despite the 
limitations of small discovery cohorts, valuable data can 
Fig. 3  ATP10B disease mutations represent loss of function. a Pro-
tein expression of HeLa cells stably overexpressing flag-tagged 
CDC50A alone (–) or in combination with ATP10B WT, the cata-
lytic variants p.E210A or p.D433N, the identified variants p.R153*, 
p.T161N, p.G393W, p.G648R, p.G671R/p.N865K, p.V748L, 
p.E993A, p.I1038T and p.I1222T or the polymorphism p.C217R. 
Immunoblotting was performed with primary antibodies against 
ATP10B, the CDC50A Flag-tag and GAPDH, which was used as 
a loading control. Immunoblots presented are representative of 3 
independent observations. b All ATP10B variants are expressed to 
comparable protein levels, except for p.R153* (based on three inde-
pendent blots for which the average ATP10B/GAPDH expression 
is depicted in the bar graph). c Microsomal fractions of the afore-
mentioned stable cell lines were compared for their ATPase activity 
via an ADP Glo luciferase assay (normalized as % of WT ATP10B 
ATPase activity). Microsomes of HeLa cells expressing WT, clinical 
and control variants of ATP10B were compared for their capacity to 
translocate NBD-PC (d) or NBD-GluCer (e) at 4 h (37 °C) post ATP 
addition. Data are expressed as relative to the WT control. f, g PD-
associated and catalytic ATP10B mutants fail to protect HeLa cells 
against rotenone and  MnCl2 toxicity. The HeLa cell lines stably over-
expressing CDC50A alone (–) or in conjunction with ATP10B, cat-
alytic controls, clinical variants or the polymorphism were exposed 
to either rotenone (R, 1 µM, f) or  MnCl2 (M, 1 mM, g) for 48 h, in 
comparison to DMSO control (C), prior to cell death analysis by 
propidium iodide (PI) based flow cytometry. All data are presented 
as the mean of three independent experiments ± SEM. Significance 
was assessed by one way ANOVA with Dunnett’s (to ATP10B 
WT) post hoc corrections, whereby **P < 0.01, ***P < 0.001 and 
****P < 0.0001
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be obtained through replication in independent and larger 
cohorts. Anyway, replication of our findings in independ-
ent and larger cohorts is needed to provide statistical asso-
ciation data allowing to estimate the frequency of ATP10B 
compound heterozygous PD and DLB carriers [11, 53, 92].
ATP10B mRNA is mainly expressed in the gastrointesti-
nal track and the brain. Interestingly, Lewy body pathology 
is also observed in the enteric nervous system of PD patients 
[18, 115] and the majority of PD patients develop eventu-
ally gastrointestinal disorders such as dysphagia, constipa-
tion and gastroesophageal reflux. The incidence of gastro-
intestinal disorders in PD patients increases over time and 
reaches approximately 65% four years after PD diagnosis 
[66]. We observed a reduction in ATP10B mRNA expres-
sion in the medulla oblongata and the substantia nigra of 
idiopathic patients compared to control individuals, which 
could result in reduced ATP10B functionality and might, at 
least partially, drive pathology. Otherwise, ATP10B expres-
sion might become downregulated in response to PD-related 
pathological insults.
Our biochemical results confirm that ATP10B func-
tionally belongs to the ATP10A/D sub-class of human 
lipid flippase isoforms that share highly conserved func-
tional domains for GluCer and PC transport, pointing to a 
Fig. 4  ATP10B knockdown sensitizes cells to rotenone and induces 
lysosomal dysfunction. a, b Immunoblot analysis confirms expres-
sion and knockdown of ATP10B protein in human WM-115 mela-
noma cells normalized to GAPDH as loading control. Two inde-
pendent microRNA based short-hairpins (mir) were used to generate 
stable knockdown cells (mir2 and mir3). mirFluc serves as a control 
cell line that was transduced with a mir against the firefly luciferase 
gene (Fluc). Immunoblot is a representative example of 3 independ-
ent experiments with densitometry represented in a bar graph (b). 
c The effect of ATP10B knockdown was assessed on the sensitiv-
ity of WM-115 cells to increasing concentrations of rotenone (Rot). 
Propidium iodide (PI) exclusion (1 µg/ml, 5 min) based flow cytom-
etry was used as a readout for cell death. d–h The effect of ATP10B 
knockdown on lysosomal functionality was assessed in the WM-115 
mirFluc control cell line in parallel with two ATP10B knockdown 
models under basal and rotenone (1  µM, 24  h) conditions. d Lyso-
somal morphology was assessed by immunofluorescent staining to 
LAMP1. DAPI was used to highlight the nuclei. Scale bar 5  µm. e 
Images from (d) were captured by confocal microscopy, and mean 
fluorescence intensity (MFI) was depicted in a bar graph (e). f pH 
measurement based on FITC-dextran analysis. Cells were treated with 
50 µg/ml FITC-dextran for 72 h. 24 h prior to the experiment rote-
none (Rot, 1  µM) was added to the relevant conditions. Lysosomal 
pH was assessed ratio-metrically by flow cytometry and pH calcu-
lated by extrapolation from a pH standard curve generated from cells 
exposed with monensin containing pH defined buffers (pH 3–8). BAF 
A1 (200 nM), an inhibitor of the lysosomal proton pump, was used as 
a control to increase the pH. g Lysosomal degradative capacity was 
assessed by DQ-BSA, which following endocytic uptake is degraded 
in the lysosome leading to an increased fluorescence. Cells were 
exposed to 5 µg/ml DQ-BSA for 1 h prior to the treatment with either 
Rot or BAF A1 for a subsequent 4 h. General lysosomal proteolysis 
was then measured. h Lysosomal membrane integrity was assessed 
by an acridine orange based assay. Cells were treated with 5  µg/ml 
acridine orange (15 min, 37 °C), washed and treated with either Rot 
(1 µM) or BAF A1 (200 nM) for 4 h. Lysosomal membrane intactness 
was assessed by flow cytometry. Statistical validation was assessed by 
one way ANOVA with Dunnett’s post hoc and differences between 
cell line sensitivities were assessed by two way ANOVA’s whereby; 
*P < 0.05, **P < 0.01, ****P < 0.0001
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physiological role of the ATP10A, B and D transporters in 
GluCer/PC uptake or subcellular redistribution [94]. Inter-
estingly, we here established that ATP10B transports both 
GluCer and PC synergistically via a non-competing translo-
cation mechanism, suggesting distinct substrate binding sites 
and translocation pathways. Mutations in the yeast Dnf1/2 
and human ATP10A/D isoforms were able to separate the 
GluCer/PC substrate specificity, indicating that GlcCer and 
PC are coordinated differently and may indeed be trans-
ported by independent pathways [94]. The results from our 
competition assay indicate that besides GluCer and PC, also 
GluSph and sphingomyelin may be transported by ATP10B. 
This can be rationalized by similarities in the lipid head 
groups of the transported lipid species, which is a major 
determinant of substrate specificity in lipid flippases [8, 84]. 
Further studies are needed to pinpoint more precisely which 
(combination) of the transported lipids of ATP10B may be 
responsible for the observed neuroprotective effect.
ATP10B demonstrates a cell protective effect towards 
the pesticide rotenone and heavy metal  MnCl2, two agents 
that represent independent modes of action and that are 
considered as environmental risk factors for PD. Inter-
estingly, like ATP10B, ATP13A2 (PARK9) is another 
late endo-/lysosomal P-type ATPase that is genetically 
Fig. 5  Loss of ATP10B expression sensitizes cortical neurons to PD-
related stressors. a–c ATP10B expression in isolated murine cortical 
neurons and after knockdown with lentiviral shRNA transduction 
(mir5 and mir7) was assessed by qRT-PCR (a) and immunoblotting 
(b, c). ATP10B, as well as total (t) and cleaved (c) caspase 3 were 
probed via immunoblotting (b). GAPDH was used as a loading con-
trol. Bar graphs represent the densitometrical analysis of ATP10B 
and cleaved caspase 3 expression (c). d, e ATP10B is expressed in 
the late endo-/lysosomal compartment of isolated mouse cortical neu-
rons. d ATP10B (red) co-localization with the endocytic compart-
ments (green) was performed toward Rab11 (recycling endosomes), 
Rab5 (early endosomes), Rab7 (late endosomes), Lamp1 (late endo/
lysosomes) or Lamp2 (lysosomes). DAPI was used as a marker of the 
nucleus. Scale 10 µm. e Pearson’s co-efficient for the co-localization 
probability of ATP10B with the aforementioned endocytic compart-
ments. f–i ATP10B knockdown induces neuronal death, which is 
exacerbated by rotenone or manganese  (MnCl2) treatment. ATP10B 
was knocked down (mir5, mir7) in cortical neurons, in comparison 
to control (mirFluc). Neurons were subsequently exposed to 50  nM 
rotenone or 0.5  mM  MnCl2 (24  h) and cell death was assessed by 
cleaved caspase 3 antibody (f–g, red) or TUNEL (h–i, red) staining 
based confocal microscopy. DAPI (blue) was used as a marker of the 
nucleus. Scale bar 25  µm. Immunoblots are representative of three 
independent experiments, whereas quantification of the caspase 3/
DAPI (g) or TUNEL/DAPI (i) ratio is presented in bar graphs and 
expressed in percentage. All data depict averages of a minimum of 
three independent experiments ± SEM. Significance was assessed by 
one-way ANOVA with either Dunnett’s post hoc (e, to Rab11; a, c to 
mirFluc) or Tukey’s (g, i) post hoc whereby, 1 mark P < 0.05, 2 marks 
P < 0.01, 3 marks P < 0.001, 4 marks P < 0.0001
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linked to PD [28, 90]. As a lysosomal polyamine exporter, 
ATP13A2 provides protection to rotenone and  MnCl2 [68, 
111, 112], and also maintains lysosomal functionality and 
membrane integrity [111], pointing to a remarkable syn-
ergy between the two lysosomal export systems. Rotenone 
is a mitochondrial complex I inhibitor, whereas  MnCl2 
may inhibit the mitochondrial respiratory chain at the level 
of complex II [43, 102]. By redistributing lipids within 
the cell and/or by maintaining lysosomal functionality and 
membrane integrity, ATP10B may provide protection to 
mitochondrial dysfunction or oxidative stress.
Alterations in sphingolipid lipid homeostasis are linked 
to lysosomal dysfunction and involved in PD pathogenesis 
[65, 78, 87]. Heterozygous mutations in GBA1 are asso-
ciated with an increased risk for PD [30, 99]. Moreover, 
both α-synuclein and the phospholipase PLA2G6, the latter 
implicated in neurodegeneration with brain iron accumula-
tion and early-onset dystonia parkinsonism [52, 56], have 
Fig. 6  Increased neuronal sensitivity of ATP10B knockdown can be 
recovered by active ATP10B. a, b Control (mirFluc) and ATP10B 
knockdown (mir5 and mir7) cortical neurons were transduced with 
Fluc (Firefly luciferase), human WT ATP10B or p.D433N mutant. 
Following ATP10B recovery neurons were exposed to rotenone (Rot, 
50 nM, 24 h) and sensitivity assessed by TUNEL (red) staining and 
confocal microscopy. DAPI (blue) was used as a reference. b Percent-
age of DAPI stained cells that were positive for TUNEL is expressed 
in a boxplot. c, d The capacity of ATP10B to recover lysosomal func-
tionality under basal and rotenone (50 nM) conditions was assessed 
via the DQ-BSA assay (green 10 µg/ml). DAPI was used to visualize 
the nuclei (blue). d The mean fluorescent intensity of each condition 
in (c) was quantified and represented in a boxplot graph. White scale 
bar in cell images corresponds to 25 µm. All other data depict aver-
ages of a minimum of three independent experiments ± SEM. Statisti-
cal validation was assessed by one way ANOVA with Dunnett’s post 
hoc and differences between cell line sensitivities were assessed by 
two way ANOVA’s whereby; * versus control mirFluc (Fluc), $ ver-
sus rotenone in the mirFluc, and # is cellular control. 1 mark P < 0.05, 
2 marks P < 0.01, 3 marks P < 0.001, 4 marks P < 0.0001
1019Acta Neuropathologica (2020) 139:1001–1024 
1 3
been associated with changes in lysosomal ceramide lev-
els, though the exact mechanisms are still unknown [57, 64, 
69]. Additionally, compelling associations between PD and 
genes involved in or linked to sphingolipid metabolism are 
emerging from genetic studies, including SMPD1, GALC 
and SCARB2 [7, 21, 39]. Here, we identified ATP10B as 
a novel putative PD risk gene and key player in lysosomal 
functioning and sphingolipid metabolism. As a lysosomal 
GluCer and possible GluSph exporter, ATP10B may be con-
sidered as a direct regulator of the lysosomal GluCer/GluSph 
content, similar as GCase, which hydrolyzes glucose moie-
ties from both GluCer and GluSph within lysosomes [30]. 
ATP10B may therefore synergize with GCase to maintain 
low levels of GluCer or GluSph in the lysosome in a sub-
set of tissues, including the brain, where both ATP10B and 
GCase expression is observed. Similar to ATP10B muta-
tions, GBA1 mutations lead to a reduced or loss of func-
tion, which in turn results in a disturbed lysosomal GluCer/
GluSph homeostasis and lysosomal dysfunction [37, 57]. 
Changes in GluCer levels may affect the V-Type ATPase 
activity at the lysosome [109], whereby loss of GluCer hin-
ders compartment acidification, or alternatively accumu-
lation of GluCer or its breakdown products may directly 
affect lysosomal membrane integrity. Loss of GCase func-
tion and elevated GluCer levels were also shown to increase 
α-synuclein aggregation, mitochondrial impairment, inflam-
mation, and endoplasmic reticulum stress, though the exact 
mechanism is unclear [30, 57, 69, 100, 104]. Elevated lys-
osomal GluCer levels may be a common consequence of 
both dysfunctional ATP10B and GCase. GluCer reduction 
therapy by pharmacological inhibition of GluCer synthase 
may therefore be considered in PD treatment, which is cur-
rently in clinical trials for GBA1-associated PD [96]. We 
further propose that increasing ATP10B functionality for 
lysosomal substrate reduction therapy may be an attractive 
strategy to prevent lysosomal GluCer accumulation.
ATP10B dysfunction also diminishes lysosomal PC 
export, which may further contribute to the disease mecha-
nism. Indeed, the PC lipid composition was shown to be 
disturbed in the substantia nigra of a PD rat model treated 
with 6-hydroxydopamine [36]. Moreover, loss of function 
mutations in PLA2G6, encoding a phospholipase involved 
in repair of oxidative damage to membrane phospholip-
ids, membrane remodeling and iron homeostasis, are also 
shown to affect neuronal lipid homeostasis [14, 83, 98]. 
Loss of ATP10B activity increases neuronal stress in basal 
conditions, which is exacerbated, and results in enhanced 
cell death, in the presence of rotenone or  MnCl2, two envi-
ronmental risk factors of PD [38]. Lysosomal PC and/or 
GluCer transport may be relevant during oxidative stress 
to replace damaged lipids and provide membrane integrity, 
or by regulating lysosomal membrane dynamics during 
vesicular budding or fusion. To prevent toxicity and cell 
death, neurons heavily rely on the endo-/lysosomal sys-
tem for the efficient removal of damaged mitochondria and 
toxic proteins, such as α-synuclein, using cell-autonomous 
(e.g. autophagy) and cell non-autonomous (e.g. exosome 
export) pathways [3]. Lysosomal dysfunction is one of the 
key players in PD pathology, therefore strategies aiming 
at improving lysosomal health and functionality may be 
considered for PD treatment [70].
In conclusion, we identified ATP10B as a PD risk gene 
and functionally characterized ATP10B as a late endo-/
lysosomal GluCer/PC flippase that regulates lysosomal 
functionality and provides neuroprotection. All disease-
associated compound heterozygous ATP10B mutant alleles 
presented impaired functional activities of ATP10B, sug-
gesting that reduced lysosomal GluCer/PC export may 
increase PD risk. As even risk alleles with moderate effect 
sizes are beneficial to consider new therapeutic strategies 
[54], we provide a new potential target to tackle PD.
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